Guideline Updates Redefining Squamous Cell Carcinoma of the Anal Canal Care
Project Oncology®Guideline Updates Redefining Squamous Cell Carcinoma of the Anal Canal Care
Integrating Guideline Updates in Squamous Cell Carcinoma of the Anal Canal
Project Oncology®Integrating Guideline Updates in Squamous Cell Carcinoma of the Anal Canal
ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
Project Oncology®ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
CRC Screening Strategies: Balancing Accuracy, Access, and Adherence
On the Frontlines of Colorectal CancerCRC Screening Strategies: Balancing Accuracy, Access, and Adherence
The Changing Landscape of CRC Screening and Prevention
On the Frontlines of Colorectal CancerThe Changing Landscape of CRC Screening and Prevention
Perioperative Immunotherapy Strategies in Resectable NSCLC Care
Project Oncology®Perioperative Immunotherapy Strategies in Resectable NSCLC Care
- advertisement
- 4 questions
- 3 questions
- 4 questions
- 2 questions
- 10 questions
- 4 questions
- advertisement
On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Project Oncology®On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Evaluating EFS and Surgical Outcomes in Resectable NSCLC: Insights From a Clinical Trial
Medical Industry FeatureEvaluating EFS and Surgical Outcomes in Resectable NSCLC: Insights From a Clinical Trial
Early CAR T Cell Therapy Referral: The Missing Piece in Blood Cancer Treatment
Project Oncology®Early CAR T Cell Therapy Referral: The Missing Piece in Blood Cancer Treatment
Harnessing the Immune Power: A Uniquely Designed PD-1 Inhibitor for Esophageal Cancer
Project Oncology®Harnessing the Immune Power: A Uniquely Designed PD-1 Inhibitor for Esophageal Cancer
Latest TROP2 ADC Approval for HR+ HER2- Metastatic Breast Cancer
Medical Industry FeatureLatest TROP2 ADC Approval for HR+ HER2- Metastatic Breast Cancer
- 04/10/2026
- 04/10/2026
- 04/09/2026
- 04/09/2026
- 04/08/2026
- 04/08/2026